{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:44:18Z","timestamp":1786981458343,"version":"build-2736575974"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2010,7,16]],"date-time":"2010-07-16T00:00:00Z","timestamp":1279238400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurochem Res"],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1007\/s11064-010-0214-3","type":"journal-article","created":{"date-parts":[[2010,7,14]],"date-time":"2010-07-14T23:30:36Z","timestamp":1279150236000},"page":"1546-1556","source":"Crossref","is-referenced-by-count":40,"title":["Neuroprotection of Pramipexole in UPS Impairment Induced Animal Model of Parkinson\u2019s Disease"],"prefix":"10.1007","volume":"35","author":[{"given":"Chao","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjie","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Janokovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weidong","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,7,16]]},"reference":[{"key":"214_CR1","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1385\/JMN:24:3:425","volume":"24","author":"H Snyder","year":"2004","unstructured":"Snyder H, Wolozin B (2004) Pathological proteins in Parkinson\u2019s disease: focus on the proteasome. J Mol Neurosci 24:425\u2013442","journal-title":"J Mol Neurosci"},{"key":"214_CR2","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1146\/annurev.neuro.28.061604.135718","volume":"28","author":"DJ Moore","year":"2005","unstructured":"Moore DJ, West AB, Dawson VL, Dawson TM (2005) Molecular pathophysiology of Parkinson\u2019s disease. Ann Rev Neurosci 28:57\u201387","journal-title":"Ann Rev Neurosci"},{"key":"214_CR3","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1177\/1073858408319974","volume":"15","author":"W Le","year":"2009","unstructured":"Le W, Chen S, Jankovic J (2009) Etiopathogenesis of Parkinson disease: a new beginning? Neuroscientist 15:28\u201335","journal-title":"Neuroscientist"},{"key":"214_CR4","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1212\/WNL.61.6_suppl_3.S12","volume":"61","author":"P Barone","year":"2003","unstructured":"Barone P (2003) Clinical strategies to prevent and delay motor complications. Neurology 61:S12\u2013S16","journal-title":"Neurology"},{"key":"214_CR5","first-page":"682","volume":"73","author":"J Jankovic","year":"2006","unstructured":"Jankovic J (2006) An update on the treatment of Parkinson\u2019s disease. Mt Sinai J Med 73:682\u2013689","journal-title":"Mt Sinai J Med"},{"key":"214_CR6","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1016\/S0140-6736(02)11668-0","volume":"360","author":"CE Clarke","year":"2002","unstructured":"Clarke CE, Guttman M (2002) Dopamine agonist monotherapy in Parkinson\u2019s disease. Lancet 360:1767\u20131769","journal-title":"Lancet"},{"key":"214_CR7","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1212\/WNL.49.3.724","volume":"49","author":"KM Shannon","year":"1997","unstructured":"Shannon KM, Bennett JP Jr, Friedman JH (1997) Efficacy of pramipexole a novel dopamine agonist, in mild to moderate Parkinson\u2019s disease. The pramipexole study group. Neurology 49:724\u2013728","journal-title":"Neurology"},{"key":"214_CR8","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1185\/03007990903364954","volume":"25","author":"S Albrecht","year":"2009","unstructured":"Albrecht S, Buerger E (2009) Potential neuroprotection mechanisms in PD: focus on dopamineagonist pramipexole. Curr Med Res Opin 25:2977\u20132987","journal-title":"Curr Med Res Opin"},{"key":"214_CR9","doi-asserted-by":"crossref","first-page":"389","DOI":"10.2165\/00002512-200118060-00001","volume":"18","author":"WD Le","year":"2001","unstructured":"Le WD, Jankovic J (2001) Are dopamine receptor agonists neuroprotective in Parkinson\u2019s disease? Drugs Aging 18:389\u2013396","journal-title":"Drugs Aging"},{"key":"214_CR10","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0304-3940(00)00853-3","volume":"281","author":"LL Zou","year":"2000","unstructured":"Zou LL, Xu J, Jankovic J, He Y, Appel SH, Le W (2000) Pramipexole inhibits lipid peroxidation and reduces injury in the substantia nigra induced by the dopaminergic neurotoxin 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine in C57BL\/6 mice. Neurosci Lett 281:167\u2013170","journal-title":"Neurosci Lett"},{"key":"214_CR11","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1046\/j.1471-4159.1998.71010295.x","volume":"71","author":"DS Cassarino","year":"1998","unstructured":"Cassarino DS, Fall CP, Smith TS, Bennett JP Jr (1998) Pramipexole reduces reactive oxygen species production in vivo and in vitro and inhibits the mitochondrial permeability transition produced by the parkinsonian neurotoxin methylpyridinium ion. J Neurochem 71:295\u2013301","journal-title":"J Neurochem"},{"key":"214_CR12","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.coph.2006.11.004","volume":"7","author":"JN Joyce","year":"2007","unstructured":"Joyce JN, Millan MJ (2007) Dopamine D3 receptor agonists for protection and repair in Parkinson\u2019s disease. Curr Opin Pharmacol 7:100\u2013105","journal-title":"Curr Opin Pharmacol"},{"key":"214_CR13","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1002\/ana.21832","volume":"66","author":"CW Olanow","year":"2009","unstructured":"Olanow CW, Kordower JH (2009) Modeling Parkinson\u2019s disease. Ann Neurol 66:432\u2013435","journal-title":"Ann Neurol"},{"key":"214_CR14","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1038\/81834","volume":"3","author":"R Betarbet","year":"2000","unstructured":"Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT (2000) Chronic systemic pesticide exposure reproduces features of Parkinson\u2019s disease. Nat Neurosci 3:1301\u20131306","journal-title":"Nat Neurosci"},{"key":"214_CR15","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/978-3-211-45295-0_41","volume":"70","author":"GU H\u00f6glinger","year":"2006","unstructured":"H\u00f6glinger GU, Oertel WH, Hirsch EC (2006) The rotenone model of parkinsonism\u2013the five years inspection. J Neural Transm Suppl 70:269\u2013272","journal-title":"J Neural Transm Suppl"},{"key":"214_CR16","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.pharmthera.2007.04.001","volume":"114","author":"F Sun","year":"2007","unstructured":"Sun F, Kanthasamy A, Anantharam V, Kanthasamy AG (2007) Environmental neurotoxic chemicals-induced ubiquitin proteasome system dysfunction in the pathogenesis and progression of Parkinson\u2019s disease. Pharmacol Ther 114:327\u2013344","journal-title":"Pharmacol Ther"},{"key":"214_CR17","first-page":"664","volume":"1792","author":"C Cook","year":"2009","unstructured":"Cook C, Petrucelli L (2009) A critical evaluation of the ubiquitin-proteasome system in Parkinson\u2019s disease. Biochem Biophys Acta 1792:664\u2013675","journal-title":"Biochem Biophys Acta"},{"key":"214_CR18","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.molcel.2004.12.021","volume":"17","author":"EJ Bennett","year":"2005","unstructured":"Bennett EJ, Bence NF, Jayakumar R, Kopito RR (2005) Global impairment of the ubiquitin-proteasome system by nuclear or cytoplasmic protein aggregates precedes inclusion body formation. Mol Cell 17:351\u2013365","journal-title":"Mol Cell"},{"key":"214_CR19","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.neurobiolaging.2005.08.012","volume":"27","author":"KS McNaught","year":"2006","unstructured":"McNaught KS, Olanow CW (2006) Protein aggregation in the pathogenesis of familial and sporadic Parkinson\u2019s disease. Neurobiol Aging 27:530\u2013545","journal-title":"Neurobiol Aging"},{"key":"214_CR20","doi-asserted-by":"crossref","first-page":"8189","DOI":"10.1523\/JNEUROSCI.2218-08.2008","volume":"28","author":"L Bedford","year":"2008","unstructured":"Bedford L, Hay D, Devoy A, Paine S, Powe DG, Seth R, Gray T, Topham I, Fone K, Rezvani N, Mee M, Soane T, Layfield R, Sheppard PW, Ebendal T, Usoskin D, Lowe J, Mayer RJ (2008) Depletion of 26S proteasomes in mouse brain neurons causes neurodegeneration and Lewy-like inclusions resembling human pale bodies. J Neurosci 28:8189\u20138198","journal-title":"J Neurosci"},{"key":"214_CR21","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.bbrc.2005.05.150","volume":"333","author":"X Zhang","year":"2005","unstructured":"Zhang X, Xie WJ, Qu S, Pan T, Wang X, Le W (2005) Neuroprotection by iron chelator against proteasome inhibitor-induced nigral degeneration. Biochem Biophys Res Commun 333:544\u2013549","journal-title":"Biochem Biophys Res Commun"},{"key":"214_CR22","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1096\/fj.07-8386com","volume":"21","author":"W Zhu","year":"2007","unstructured":"Zhu W, Xie WJ, Pan TH, Jankovic J, Li J, Youdim MB, Le W (2007) Prevention and restoration of lactacystin-induced nigrostriatal dopamine neuron degeneration by novel brain-permeable iron chelators. FASEB J 21:3835\u20133844","journal-title":"FASEB J"},{"key":"214_CR23","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1126\/science.290.5497.1717","volume":"290","author":"DJ Klionsky","year":"2000","unstructured":"Klionsky DJ, Emr SD (2000) Autophagy as a regulated pathway of cellular degradation. Science 290:1717\u20131721","journal-title":"Science"},{"key":"214_CR24","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/S1474-4422(07)70076-5","volume":"6","author":"M Martinez-Vicente","year":"2007","unstructured":"Martinez-Vicente M, Cuervo AM (2007) Autophagy and neurodegeneration: when the cleaning crew goes on strike. Lancet Neurol 6:352\u2013361","journal-title":"Lancet Neurol"},{"key":"214_CR25","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/nature04723","volume":"441","author":"M Komatsu","year":"2006","unstructured":"Komatsu M, Waguri S, Chiba T, Murata S, Iwata J, Tanida I, Ueno T, Koike M, Uchiyama Y, Kominami E, Tanaka K (2006) Loss of autophagy in the central nervous system causes neurodegeneration in mice. Nature 441:880\u2013884","journal-title":"Nature"},{"key":"214_CR26","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0891-0618(00)00073-9","volume":"20","author":"JR Glaser","year":"2000","unstructured":"Glaser JR, Glaser EM (2000) Stereology, morphometry, and mapping: the whole is greater than the sum of its parts. J Chem Neuroanat 20:115\u2013126","journal-title":"J Chem Neuroanat"},{"key":"214_CR27","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1111\/j.1460-9568.2005.04438.x","volume":"22","author":"F Du","year":"2005","unstructured":"Du F, Li R, Huang Y, Li X, Le W (2005) Dopamine D3 receptor-preferring agonists induce neurotrophic effects on mesencephalic dopamine neurons. Eur J Neurosci 22:2422\u20132430","journal-title":"Eur J Neurosci"},{"key":"214_CR28","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1358\/dnp.2007.20.8.1157618","volume":"20","author":"D Zemke","year":"2007","unstructured":"Zemke D, Azhar S, Majid A (2007) The mTOR pathway as a potential target for the development of therapies against neurological disease. Drug News Perspect 20:495\u2013499","journal-title":"Drug News Perspect"},{"key":"214_CR29","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.nbd.2008.06.003","volume":"32","author":"TH Pan","year":"2008","unstructured":"Pan TH, Kondo S, Zhu W, Xie W, Jankovic J, Le W (2008) Neuroprotection of rapamycin in lactacystin-induced neurodegeneration via autophagy enhancement. Neurobiol Dis 32:16\u201325","journal-title":"Neurobiol Dis"}],"container-title":["Neurochemical Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11064-010-0214-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11064-010-0214-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11064-010-0214-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:36:18Z","timestamp":1559349378000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11064-010-0214-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7,16]]},"references-count":29,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["214"],"URL":"https:\/\/doi.org\/10.1007\/s11064-010-0214-3","relation":{},"ISSN":["0364-3190","1573-6903"],"issn-type":[{"value":"0364-3190","type":"print"},{"value":"1573-6903","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,7,16]]}}}